The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Primary Sclerosing Cholangitis Treatment Market Research Report 2025

Global Primary Sclerosing Cholangitis Treatment Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1711409

No of Pages : 109

Ask Your Query
Synopsis
Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.
The global Primary Sclerosing Cholangitis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Primary Sclerosing Cholangitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Sclerosing Cholangitis Treatment.
Report Scope
The Primary Sclerosing Cholangitis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Primary Sclerosing Cholangitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Sclerosing Cholangitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals
Segment by Type
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
Segment by Application
Hospital
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Sclerosing Cholangitis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2019-2030)
2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Region
2.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2019-2024)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2023
3.5 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2025-2030)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
9.2 Latin America Primary Sclerosing Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
9.4 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.1.5 Allergan Recent Development
11.2 Glenmark
11.2.1 Glenmark Company Detail
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.2.5 Glenmark Recent Development
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Detail
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.3.5 Impax Laboratories Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.4.5 Mylan Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Detail
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Detail
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.6.5 Dr. Falk Pharma Recent Development
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Detail
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.7.5 Daewoong Pharmaceutical Recent Development
11.8 Epic Pharma
11.8.1 Epic Pharma Company Detail
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.8.5 Epic Pharma Recent Development
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Detail
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.9.5 Mitsubishi Tanabe Pharma Recent Development
11.10 Lannett
11.10.1 Lannett Company Detail
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.10.5 Lannett Recent Development
11.11 Bruschettini
11.11.1 Bruschettini Company Detail
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.11.5 Bruschettini Recent Development
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Detail
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.12.5 Shanghai Pharma Recent Development
11.13 Grindeks
11.13.1 Grindeks Company Detail
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.13.5 Grindeks Recent Development
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Detail
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.14.5 Acorda Therapeutics Recent Development
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Detail
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.15.5 Gilead Sciences Recent Development
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Detail
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.16.5 Intercept Pharmaceuticals Recent Development
11.17 Shire Plc
11.17.1 Shire Plc Company Detail
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.17.5 Shire Plc Recent Development
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Detail
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.18.5 NGM Biopharmaceuticals Recent Development
11.19 Conatus Pharmaceuticals
11.19.1 Conatus Pharmaceuticals Company Detail
11.19.2 Conatus Pharmaceuticals Business Overview
11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.19.5 Conatus Pharmaceuticals Recent Development
11.20 Durect Corporation
11.20.1 Durect Corporation Company Detail
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.20.5 Durect Corporation Recent Development
11.21 Sirnaomics
11.21.1 Sirnaomics Company Detail
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.21.5 Sirnaomics Recent Development
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Detail
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock